SCHEMBL3926546

SCHEMBL3926546

CC(=O)OCC(=O)Nc1cc(CSc2ncccc2C(=O)Nc2cccc(C(F)(F)F)c2)ccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
RXFP1 Q9HBX9 6/20 0.47
LMNA P02545 2/20 0.47
MAPT P10636 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
KDR P35968 4/20 0.47
ABL1 P00519 1/20 0.47
EGFR P00533 1/20 0.47
CSF1R P07333 1/20 0.47
PDGFRB P09619 1/20 0.47
KIT P10721 1/20 0.47
FLT1 P17948 1/20 0.47
FLT4 P35916 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3924830 0.93 KDR (0.52) MEN1KMT2AMAPTNPSR1L3MBTL1
SCHEMBL1942982 0.90 RXFP1 (0.53) MEN1KMT2ARXFP1LMNAMAPT
SCHEMBL1941842 0.89 KDR (0.46) MEN1KMT2ALMNAMAPTNPSR1
SCHEMBL1941560 0.89 MEN1 (0.51) MEN1KMT2ARXFP1LMNAMAPT
SCHEMBL3932864 0.88 KMT2A (0.51) MEN1KMT2ARXFP1LMNAMAPT
SCHEMBL1942090 0.88 MEN1 (0.48) MEN1KMT2ARXFP1LMNAMAPT
SCHEMBL3932287 0.87 KDR (0.44) MEN1KMT2ALMNANPSR1ALDH1A1
SCHEMBL3927557 0.87 KDR (0.50) KMT2ALMNAMAPTALDH1A1HPGD
SCHEMBL1941567 0.86 KMT2A (0.53) MEN1KMT2AMAPTNPSR1ALDH1A1
SCHEMBL1941869 0.86 RXFP1 (0.56) MEN1KMT2ARXFP1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7544703-B2 Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-06-09 US disclosed
US-20070149574-A1 Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein SANTEN PHARMACEUTICAL CO., LTD. (JP) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149574-A1 Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein FLT4, FLT1, TIE1 MEN1 3379/4885KMT2A 2966/4885RXFP1 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.